Trial Profile
A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Leuprorelin
- Indications Prostate cancer
- Focus Pharmacodynamics
- 02 Jun 2017 Results (n=16) of a study assessing mechanisms of resistance to ipilimumab therapy, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 13 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 02 Jul 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016, according to ClinicalTrials.gov record.